Global Finance News
09 Feb 2026, 16:31
BD (Becton, Dickinson and Company) reported first-quarter fiscal 2026 revenue of $5.3 billion, up 1.6% as reported and 0.4% on a foreign-exchange neutral basis, with New BD revenue growing 2.5% FXN. GAAP diluted EPS was $1.34, while adjusted diluted EPS reached $2.91 for the quarter ended December 31, 2025.
The company said performance exceeded expectations, supported by disciplined execution and broad-based growth across key end markets. BD also confirmed that the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a strategic pivot toward “New BD.” Management reaffirmed full-year fiscal 2026 revenue growth guidance and introduced adjusted diluted EPS guidance for New BD.
During the quarter, BD announced several strategic and product milestones, including collaborations to expand hazardous drug contamination testing, the first U.S. implementation of BD Alaris EMR Infusion Interoperability with MEDITECH, and a $110 million investment to expand U.S. production of BD Neopak glass prefillable syringes to support biologics and GLP-1 drug delivery. Additional highlights included regulatory clearance for new interventional products, portfolio expansions in continence care and surgical systems, and progress in clinical studies for vascular devices.
The company said performance exceeded expectations, supported by disciplined execution and broad-based growth across key end markets. BD also confirmed that the combination of its Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close today, marking a strategic pivot toward “New BD.” Management reaffirmed full-year fiscal 2026 revenue growth guidance and introduced adjusted diluted EPS guidance for New BD.
During the quarter, BD announced several strategic and product milestones, including collaborations to expand hazardous drug contamination testing, the first U.S. implementation of BD Alaris EMR Infusion Interoperability with MEDITECH, and a $110 million investment to expand U.S. production of BD Neopak glass prefillable syringes to support biologics and GLP-1 drug delivery. Additional highlights included regulatory clearance for new interventional products, portfolio expansions in continence care and surgical systems, and progress in clinical studies for vascular devices.
